Anthem Biosciences Ltd
Incorporated in 2006, Anthem Biosciences
Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.[1]
- Market Cap ₹ 42,696 Cr.
- Current Price ₹ 760
- High / Low ₹ 874 / 579
- Stock P/E 71.2
- Book Value ₹ 50.8
- Dividend Yield 0.00 %
- ROCE 30.7 %
- ROE 23.0 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 21.9%
Cons
- Stock is trading at 15.0 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 626 | 633 | 1,103 | 1,231 | 1,057 | 1,418 | 1,841 | 1,986 | |
| 454 | 451 | 695 | 666 | 626 | 912 | 1,151 | 1,204 | |
| Operating Profit | 172 | 182 | 408 | 566 | 431 | 505 | 690 | 782 |
| OPM % | 27% | 29% | 37% | 46% | 41% | 36% | 37% | 39% |
| 21 | 21 | 37 | 49 | 139 | 70 | 109 | 134 | |
| Interest | 18 | 20 | 17 | 10 | 9 | 9 | 9 | 7 |
| Depreciation | 61 | 62 | 62 | 58 | 64 | 81 | 78 | 94 |
| Profit before tax | 114 | 121 | 366 | 547 | 498 | 485 | 711 | 815 |
| Tax % | 32% | 23% | 26% | 26% | 23% | 23% | 29% | |
| 77 | 93 | 271 | 406 | 386 | 375 | 506 | 581 | |
| EPS in Rs | 91.97 | 110.62 | 319.77 | 462.60 | 6.76 | 6.70 | 9.05 | 10.36 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 14% |
| TTM: | 30% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 40% |
| 3 Years: | 8% |
| TTM: | 35% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 27% |
| 3 Years: | 22% |
| Last Year: | 23% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 9 | 114 | 112 | 112 | 112 |
| Reserves | 323 | 413 | 693 | 1,347 | 1,628 | 1,821 | 2,361 | 2,741 |
| 192 | 159 | 100 | 35 | 115 | 173 | 113 | 110 | |
| 194 | 207 | 232 | 228 | 136 | 219 | 249 | 387 | |
| Total Liabilities | 718 | 787 | 1,034 | 1,619 | 1,993 | 2,324 | 2,836 | 3,350 |
| 316 | 306 | 361 | 329 | 449 | 478 | 624 | 609 | |
| CWIP | 12 | 50 | 19 | 153 | 143 | 156 | 58 | 81 |
| Investments | 73 | 99 | 209 | 273 | 499 | 472 | 533 | 645 |
| 318 | 333 | 444 | 865 | 902 | 1,219 | 1,620 | 2,016 | |
| Total Assets | 718 | 787 | 1,034 | 1,619 | 1,993 | 2,324 | 2,836 | 3,350 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 196 | 166 | 278 | 333 | 319 | 164 | 440 | |
| -121 | -109 | -196 | -206 | -378 | -192 | -246 | |
| -65 | -48 | -63 | 181 | 53 | -132 | -66 | |
| Net Cash Flow | 9 | 9 | 18 | 308 | -6 | -159 | 127 |
| Free Cash Flow | 144 | 119 | 159 | 308 | 145 | 41 | 313 |
| CFO/OP | 114% | 116% | 85% | 81% | 101% | 56% | 87% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 61 | 84 | 97 | 95 | 126 | 89 |
| Inventory Days | 123 | 186 | 29 | 52 | 139 | 129 | 167 |
| Days Payable | 72 | 87 | 50 | 58 | 77 | 61 | 54 |
| Cash Conversion Cycle | 119 | 160 | 63 | 91 | 157 | 194 | 201 |
| Working Capital Days | 22 | 20 | 27 | 75 | 114 | 129 | 128 |
| ROCE % | 26% | 55% | 51% | 28% | 25% | 31% |
Insights
In beta| Mar 2010 | Mar 2012 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Custom Synthesis Capacity kL |
|
|||||||||||
| Fermentation Capacity kL |
||||||||||||
| Fixed Asset Turnover x |
||||||||||||
| Number of Employees Number |
||||||||||||
| Scientific Staff Number |
||||||||||||
| Number of Commercial Molecules Number |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
2d - Anthem Biosciences says it is not a Large Corporate; outstanding borrowing was INR 2.96 crore.
-
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
22 Apr - Board approved SR Batliboi as statutory auditor for 5 years and an upside-sharing payout of INR 1,276.83 million.
-
Announcement Under Regulation 30 Of LODR-Update In The Outcome Of The Board Meeting Held On April 22, 2026
22 Apr - Board approved S.R. Batliboi as auditor and sought approval for ₹1,276.83 million promoter payout from investor divestment.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
6 Apr - Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended Marcg 31, 2026
- Closure of Trading Window 27 Mar
Concalls
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT REC
Business Overview:[1]
ABL is a Contract Research, Development,
and Manufacturing Organization with fully integrated operations across the drug discovery, development, and manufacturing value chain. It is among the few companies in India offering capabilities in both New Chemical
Entity (NCE) and New Biological Entity (NBE) programs. The company has developed various platforms such as RNA interference (RNAi),
Antibody-Drug Conjugates (ADCs), peptides, lipids, and oligonucleotides.